These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 34906541)

  • 1. Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: Consensus document and practice guidance.
    Gil-Núñez A; Masjuan J; Montaner J; Castellanos M; Segura T; Cardona P; Tembl JI; Purroy F; Arenillas J; Palacio E
    Neurologia (Engl Ed); 2022 Mar; 37(2):136-150. PubMed ID: 34906541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: Consensus document and practice guidance.
    Gil-Núñez A; Masjuan J; Montaner J; Castellanos M; Segura T; Cardona P; Tembl JI; Purroy F; Arenillas J; Palacio E
    Neurologia (Engl Ed); 2022 Mar; 37(2):136-150. PubMed ID: 33358061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Secondary Prevention Patients Eligible for PCSK9 Inhibitors Therapy According to the Routine Clinical Practice in Spain.
    Cosin-Sales J; Sidelnikov E; Villamayor S; Fernández M; Merino-Montero S; Zamora A
    Adv Ther; 2023 Jun; 40(6):2710-2724. PubMed ID: 36525203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proprotein Convertase Subtilisin Kexin 9 Inhibitors.
    Pirillo A; Catapano AL
    Cardiol Clin; 2018 May; 36(2):241-256. PubMed ID: 29609754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
    Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
    Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholesterol and stroke: Roll of PCSK9 inhibitors.
    Castilla-Guerra L; Fernández-Moreno MC; Rico-Corral MA
    Neurologia (Engl Ed); 2019 Apr; 34(3):198-203. PubMed ID: 28549755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary and secondary prevention of stroke and cardiovascular events using evolocumab and alirocumab: Meta-analysis of randomized controlled trials.
    Shin KH; Choi HD
    Int J Clin Pharmacol Ther; 2024 Jun; 62(6):250-258. PubMed ID: 38529927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors.
    Eisen A; Giugliano RP
    Curr Opin Cardiol; 2016 Nov; 31(6):644-653. PubMed ID: 27661220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
    Tziomalos K
    Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of PCSK9 Inhibitors in Stroke Prevention.
    Moustafa B; Testai FD
    J Stroke Cerebrovasc Dis; 2021 Nov; 30(11):106057. PubMed ID: 34450482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.
    Giugliano RP; Pedersen TR; Saver JL; Sever PS; Keech AC; Bohula EA; Murphy SA; Wasserman SM; Honarpour N; Wang H; Lira Pineda A; Sabatine MS;
    Stroke; 2020 May; 51(5):1546-1554. PubMed ID: 32312223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world data on the prescription of proprotein convertase subtilisin/kexin type 9 inhibitors in high-risk patients in a tertiary medical center.
    Tsai CL; Chang YH; Su CH; Wu YJ; Yeh HI; Lin CF
    J Formos Med Assoc; 2022 Sep; 121(9):1877-1880. PubMed ID: 34852937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCSK9 inhibitors in the prevention of cardiovascular disease.
    Latimer J; Batty JA; Neely RD; Kunadian V
    J Thromb Thrombolysis; 2016 Oct; 42(3):405-19. PubMed ID: 27095708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging agents for the treatment and prevention of stroke: progress in clinical trials.
    Safouris A; Magoufis G; Tsivgoulis G
    Expert Opin Investig Drugs; 2021 Oct; 30(10):1025-1035. PubMed ID: 34555978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
    Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
    Korman M; Wisløff T
    Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):15-22. PubMed ID: 28444187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of proprotein convertase subtilisin/kexin type-9 inhibition in secondary prevention: from clinical trials to real-world experience.
    Pandey AS; Bajaj HS; Garg V; Pandey A; Verma S
    Curr Opin Cardiol; 2017 Sep; 32(5):633-641. PubMed ID: 28557865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review.
    Chang Y; Eom S; Kim M; Song TJ
    Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.